ISRCTN46806801 https://doi.org/10.1186/ISRCTN46806801

Discovery of novel biomarkers in peripheral arterial disease/metabolic syndrome

Submission date	Recruitment status	[ ] Prospectively registered
28/03/2007	Stopped	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
19/06/2007	Stopped	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
21/06/2017	Nutritional, Metabolic, Endocrine	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Jill Belch

Contact details
The Institute of Cardiovascular Research
Department of Medicine
Ninewells Hospital & Medical School
Dundee
United Kingdom
DD1 9SY
-
j.j.f.belch@dundee.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
PADBelch07

Study information

Scientific Title
Discovery of novel biomarkers in peripheral arterial disease/metabolic syndrome

Acronym
PAD Wyeth

Study objectives
The overall objective of the research proposal is to determine the occurrence of biomarkers with proven links to future cardiovascular events in patients with Peripheral Arterial Disease (PAD) and type 2 diabetes receiving various standards of care medicines including pioglitazone.

On 21/06/2007 the target number of participants was changed from 70 to 80.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Tayside Ethics Committee, 13/06/2007, ref: 07/S1401/43

Study design
Randomised double-blind placebo-controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Type 2 diabetes and peripheral arterial disease

Interventions
In the Phase 1 section of this trial, blood and urine samples will be collected for the following analyses:
1.Transcriptional analysis
2. Other assays:
2.1. E selectin
2.2. P selectin

2.3. Endothelin
2.4. C-Reactive Protein (CRP)
2.5. Isoprostanes
2.6. Intercellular Adhesion Molecules (ICAM)

Laser Doppler imaging and iontophoresisces will also be performed, as well as measuring the flow mediated dilatation and arterial stiffness using the SphygmoCor pulse wave analysis system and Intima-Media Thickness.

In the Phase 2 section of this trial either 45 mg pioglitazone (orally) or a placebo will be given for 30 days to study its effect on vascular behaviour.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Pioglitazone

Primary outcome measure
Development of new biomarkers

Secondary outcome measures
Correlate clinical parameters (e.g. walking distances) in patients with PAD and type 2 diabetes treated with various standard of care medicines to genes and protein profiling in muscle biopsies.

Overall study start date
01/04/2007

Completion date
30/06/2008

Reason abandoned (if study stopped)
Lack of funding/sponsorship

Eligibility

Key inclusion criteria
For Phase 1 study subjects with PAD and type 2 diabetes will be included. PAD will be defined as patients with classical symptoms of intermittent claudication plus an Ankle brachial Blood Pressure Index (ABPI) of <0.9, the accepted cut off level for such a diagnosis.

For Phase 2 study patients with short distance claudication (<200 yards) will be selected for the walking study, as their walking distances are more reproducible (i.e. using the standardized Gardner walking treadmill protocol no more than 25% variation from 2 consecutive treadmill tests performed at least a week apart during the screening period). Patients for this second study will be type 2 diabetic patients not receiving insulin.

Participant type(s)
Patient

Age group
Not Specified

Sex
Both

Target number of participants
80

Key exclusion criteria
1. Contraindication to thiazolidinedione group of drugs
2. Subjects taking sulphonylureas
3. Subjects with cardiovascular disease event within last three months (such as Myocardial Infarction [MI], unstable angina and stroke)
4. For Phase 2 study, subjects having more than 25% variation from 2 consecutive treadmill tests performed at least a week apart

Date of first enrolment
01/04/2007

Date of final enrolment
30/06/2008

Locations

Countries of recruitment
Scotland

United Kingdom

Study participating centre
The Institute of Cardiovascular Research
Dundee
United Kingdom
DD1 9SY

Sponsor information

Organisation
University of Dundee (UK)

Sponsor details

c/o Mr James Houston
Research and Innovation Services
University of Dundee
DD1 4HN
Dundee
Scotland
United Kingdom
DD1 4HN

Sponsor type
University/education

ROR
https://ror.org/03h2bxq36

Funder(s)

Funder type
Industry

Funder Name
Wyeth Pharmaceuticals (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration